The Lantern is described as an AI-driven revenue tool to accelerate revenue workflows, with claims of 19% increase in average deal size and automated outreach. A Champion Agent monitors personnel shifts across the customer base and improve response rates for certain teams. Lantern Pharma reports progress in 2026, cutting R&D spend by 47% while advancing multiple clinical programs, launching an AI platform with Zeta.ai and expanding an AI Center of Excellence in India to scale RADR. These developments illustrate Lantern's growth into AI-powered drug discovery partnerships, supported by ongoing financing to fuel expansion.
Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.comBrowse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comnews
www.newswire.calantern News and Updates from The Economictimes.com
economictimes.indiatimes.comLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.com